(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
3SBio Inc., an investment holding company, researches, develops, manufactures, markets, and sells biopharmaceutical products in the People's Republic of China...
Stats | |
---|---|
今日成交量 | 10.09M |
平均成交量 | 17.65M |
市值 | 14.58B |
EPS | HKD0 ( 2024-03-20 ) |
下一个收益日期 | ( HKD0 ) 2024-06-19 |
Last Dividend | HKD0.100 ( 2023-06-27 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 9.07 |
ATR14 | HKD0.0120 (0.20%) |
音量 相关性
3SBio Inc 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
3SBio Inc 相关性 - 货币/商品
3SBio Inc 财务报表
Annual | 2023 |
营收: | HKD7.82B |
毛利润: | HKD6.64B (84.98 %) |
EPS: | HKD0.620 |
FY | 2023 |
营收: | HKD7.82B |
毛利润: | HKD6.64B (84.98 %) |
EPS: | HKD0.620 |
FY | 2022 |
营收: | HKD6.86B |
毛利润: | HKD5.67B (82.69 %) |
EPS: | HKD0.780 |
FY | 2021 |
营收: | HKD6.38B |
毛利润: | HKD5.28B (82.67 %) |
EPS: | HKD0.650 |
Financial Reports:
No articles found.
3SBio Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.100 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.0685 | 2018-06-29 |
Last Dividend | HKD0.100 | 2023-06-27 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 3 | -- |
Total Paid Out | HKD0.369 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.64 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 5.29 | |
Div. Directional Score | 8.05 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
2318.HK | Ex Dividend Knight | 2023-09-11 | Semi-Annually | 0 | 0.00% | |
1286.HK | Ex Dividend Knight | 2023-08-21 | Semi-Annually | 0 | 0.00% | |
0347.HK | No Dividend Player | 2023-06-01 | Sporadic | 0 | 0.00% | |
6098.HK | Ex Dividend Junior | 2023-06-02 | Annually | 0 | 0.00% | |
1848.HK | Ex Dividend Junior | 2023-09-07 | Semi-Annually | 0 | 0.00% | |
0874.HK | Ex Dividend Knight | 2023-06-14 | Annually | 0 | 0.00% | |
0023.HK | Ex Dividend Knight | 2023-09-07 | Semi-Annually | 0 | 0.00% | |
2660.HK | Ex Dividend Knight | 2023-06-30 | Annually | 0 | 0.00% | |
1425.HK | Ex Dividend Junior | 2023-06-16 | Annually | 0 | 0.00% | |
0512.HK | Ex Dividend Knight | 2023-06-09 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.198 | 1.500 | 6.04 | 9.05 | [0 - 0.5] |
returnOnAssetsTTM | 0.0656 | 1.200 | 7.81 | 9.38 | [0 - 0.3] |
returnOnEquityTTM | 0.112 | 1.500 | 9.86 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 2.47 | 0.800 | 2.67 | 2.14 | [1 - 3] |
quickRatioTTM | 1.901 | 0.800 | 3.52 | 2.82 | [0.8 - 2.5] |
cashRatioTTM | 0.722 | 1.500 | 7.10 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.204 | -1.500 | 6.59 | -9.89 | [0 - 0.6] |
interestCoverageTTM | 23.36 | 1.000 | 2.46 | 2.46 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.485 | 2.00 | 9.84 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.353 | 2.00 | 9.82 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.344 | -1.500 | 8.62 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.850 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.300 | 1.000 | 5.99 | 5.99 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.245 | 1.000 | 9.75 | 9.75 | [0.2 - 2] |
assetTurnoverTTM | 0.331 | 0.800 | -1.128 | -0.902 | [0.5 - 2] |
Total Score | 10.81 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 8.87 | 1.000 | 9.21 | 0 | [1 - 100] |
returnOnEquityTTM | 0.112 | 2.50 | 9.91 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.353 | 2.00 | 9.88 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.778 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.485 | 2.00 | 9.84 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.152 | 1.000 | 8.71 | 0 | [0.1 - 0.5] |
Total Score | 5.29 |
3SBio Inc
3SBio Inc., an investment holding company, researches, develops, manufactures, markets, and sells biopharmaceutical products in the People's Republic of China. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; EPIAO and SEPO recombinant human erythropoietins to treat anemia; and Cipterbin for HER2-positive metastatic breast cancer in combination with chemotherapy. It also offers Mandi to treat male alopecia and alopecia areata; Xenopax for preventing acute rejection after renal transplant; Byetta for the glycemic control in patients with type 2 diabetes; Qiming Keli to treat retinopathy caused by type 2 diabetic; Aiyishu for iron-deficiency anemia; and SPARIN, an injectable low-molecular-weight heparin calcium for the treatment of prophylaxis and deep vein thrombosis, as well as for the prevention of clotting during hemodialysis. In addition, it offers Intefen, a recombinant human interferon to treat lymphatic or hematopoietic malignancies and viral infections; and Inleusin, a human interleukin2 for the treatment of renal cell carcinoma, melanoma, and thoracic fluid build-up. Further, the company provides trading, project management and consultation, technology, and agricultural services. It has collaboration agreements with companies, such as AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and DanaFarber Cancer Institute. The company was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。